ReviewNeuro-oncology advances
Proteomics in IDH-mutated diffuse lower-grade glioma: a scoping review.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Coordinated Mitochondrial Genome Expression Program Marks a Differentiated Neural-Lineage and Synaptic Transcriptional State in Lower-Grade Glioma.International journal of molecular sciences · 2026Article
- AMPAR Subunit Gene Expression Marks a Synaptic Transcriptional State in Lower-Grade Glioma.Brain sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Therapeutic options and biomarkers for isocitrate dehydrogenase-mutated (IDHmut) diffuse lower-grade glioma (dLGG), WHO grade 2-3, are limited. Global quantitative proteomics has aided the discovery of novel markers and drug targets across various pathologies. This review aimed to summarize current proteomic findings in IDHmut dLGG. Methods: PubMed, Embase, and Scopus were searched following PRISMA-ScR guidelines. Studies examining quantitative proteomics in IDHmut dLGG with liquid chromatography-mass spectrometry in adult human samples were included. Studies with only high-grade gliomas, without IDHmut, using xenografts, or cell line samples, and reviews were excluded. Results: In total, 1,902 records were identified; 85 full-texts were retrieved, and 13 met the inclusion criteria. Twelve studies were cross-sectional and one longitudinal. Two studies used cerebrospinal fluid samples, while seven used fresh frozen and five formalin-fixed paraffin-embedded (FFPE) tissue samples. There was a large heterogeneity in aims, sample types, and analytical techniques. The most recurrent finding was altered energy metabolism, mostly related to the tricarboxylic acid cycle, compared to IDH-wildtype gliomas. IDHmut dLGG proteomic profile was distinct from other brain tumors, including IDH-wildtype glioblastoma, IDHmut grade 4 astrocytomas, and grade 1 gliomas or normal brain. Conclusions: IDHmut dLGG has a unique proteome that may be leveraged for biomarkers and therapeutic discovery. Proteomic findings indicate a particular dependency on glutamate metabolism to sustain the citric acid cycle and energy production. Although current proteomic knowledge is limited and fragmented, technological advancements present an opportunity for large-scale studies using FFPE samples, advancing proteomic knowledge and precision medicine in IDHmut dLGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.